Ask AI
ProCE Banner Activity

Switch to LA CAB + RPV in People With HIV and Detectable Viral Load in OPERA Cohort

Conference Coverage
Slideset

Real-world results from the OPERA cohort suggest LA CAB + RPV is effective among individuals with HIV-1 RNA > 50 copies/mL and difficulties taking daily oral ART, but injection adherence was moderate.

Released: July 16, 2025

Expiration: January 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner